About Kevin Lind
Kevin Lind is a chief executive officer and director at Apnimed.
Kevin Lind reports to the SEC as a director or officer of 4 public companies, including Avalo Therapeutics (AVTX), Longboard Pharmaceuticals (LBPH) and Arena Pharmaceuticals (ARNA).
Kevin Lind first appears on SEC filings in 2016.
Experience
This experience comes from Kevin Lind's profile and from SEC filings. For roles taken from filings, the years are when the filings name Kevin Lind in the role, so the role may have started earlier or lasted longer.
Apnimed, Inc. Current
Chief Executive Officer and director
2025 – Present · Public company (APMD)
Develops oral medicines for people with sleep apnea and other sleep-related breathing diseases.
AI
Avalo Therapeutics, Inc.
Director
2025 – 2026 · Public company (AVTX)
LI
Longboard Pharmaceuticals, Inc.
President and CEO, director
2020 – 2024 · Public company (LBPH)
AI
Arena Pharmaceuticals Inc.
Executive VP and CFO
2016 – 2020 · Public company (ARNA)
TP
TPG Special Situations Partners
Principal
2009 – 2016
TC
TPG-Axon Capital
Pharma Partners
2006 – 2009
LB
Lehman Brothers Investment Banking
Associate (2004 – 2006)
Analyst/Associate (1998 – 2002)
1998 – 2006
Key Colleagues at Startups
The people Kevin Lind works with at each company, as listed on that company's latest Form D.
Apnimed, Inc. · Form D, Mar 27, 2026
LM
Lawrence Miller
Executive officer and director
Paul Fonteyne
Director
DM
Dennis Molnar
Executive officer
Barry Wohl
Chief Business Officer
JA
Joseph Avellone
Director
FB
Francois Beaubien
Director
Chris Dimitropoulos
Director
IC
Isaac Cheng
Director
GS
Gary Sender
Director
RB
Ramzi Benamar
Chief Financial Officer